Ultragenyx Pharmaceutical Inc (MEX:RARE)
MXN 751.98 0 (0%) Market Cap: 64.70 Bil Enterprise Value: 57.96 Bil PE Ratio: 0 PB Ratio: 23.46 GF Score: 70/100

Ultragenyx Pharmaceutical Inc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript

Jun 09, 2020 / 07:50PM GMT
Release Date Price: MXN1323.83
Salveen Jaswal Richter
Goldman Sachs Group, Inc., Research Division - VP

Good afternoon, everyone. I'm Salveen Richter, biotechnology analyst at Goldman Sachs, and we're pleased to have Ultragenyx here with us today. And we have Emil Kakkis, CEO.

Questions & Answers

Salveen Jaswal Richter
Goldman Sachs Group, Inc., Research Division - VP

With that, Emil, maybe to start, you have multiple events set to play out this year with advancement of your gene therapy portfolio in addition to commercial launches. Could you just walk us through the catalyst path for maybe the next 12 months with regard to your portfolio?

Emil D. Kakkis
Ultragenyx Pharmaceutical Inc. - President, CEO & Director

Sure, Salveen. Thanks for speaking with me today, and I'll give you kind of an update of where the catalyst [work] for the coming year. It's already June of the year, and it's been quite a year, from COVID and everything else going on in the world. There's been a lot of distractions and pain and suffering. But fortunately

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot